We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.

Publish fast. Openly. Without restrictions.

An open access publishing platform supporting data deposition and sharing: the perfect publication avenue for researchers working in fast paced fields such as infectious diseases research and epidemiology.

Submit your research

F1000Research: Rapid dissemination of research when it’s needed most

F1000Research facilitates the rapid and transparent sharing of research by providing fast, open publication alongside access to any underlying data, software code and resources. All research articles are reviewed post publication, with expert peer review reports freely available.

F1000Research is particularly suited to fast paced areas of research such as infectious diseases research and epidemiology, where immediate access to robust and rigorous science is essential for informing clinical and public health responses in real time.

F1000Research has set up a dedicated section within the Disease Outbreaks Gateway for the publication of COVID-19 related research. We welcome all types of publications related to coronavirus, including but not limited to: clinical trials, clinical case reports, epidemiological modelling, transmission dynamics, collaboratively written policies, protocols, and any other information that needs to be shared rapidly.

Articles published on F1000Research are subject to our Article Processing Charges. For COVID-19 research there is no charge to publish posters, slides and research-related outputs that do not require peer review.

Submit your research 

The Disease Outbreaks Gateway on F1000Research

This Gateway aggregates and showcases research related to global disease outbreaks, including a section on COVID-19 related research articles.
Browse the Gateway

Our median publication times* for COVID-19 articles are:

Benefits of the F1000Research publishing model

Rapid publication

See your article published in a matter of days, fully citable and ready for peer review. COVID-19 papers take a median of seven days from submission to publication, and 16 days from publication to peer review.

Wide range of research

We support the publication of research protocols and methods (as Registered Reports as required), data articles, software tool articles and case studies, alongside systematic reviews and research articles.

Interactive figures

We can include interactive data tables and figures to support longitudinal time series and quantitative data, providing a quick, easy and cost-effective way to provide updates.

Article versioning

Our versioned publication system means that updates to studies can be made easily and quickly, without the need to publish a new paper. Versions are linked and are individually citable, and older versions will display a clear notification that a new version has been uploaded so that readers are always kept up to date with the latest developments in your work.

Alternative research outputs

We also publish research-related outputs that do not require peer review, such as policy documents, guidelines and technical reports that may, for example, guide health care and disease management practices, for health and allied professionals in such emergencies. We also publish posters and slide decks.

Submit your research


COVID-19 Rapid Review Initiative

We are delighted to be working together with other scholarly publishers to maximize the efficiency of peer review, ensuring that key work related to COVID-19 is reviewed and published as quickly and openly as possible. Michael Markie, Publishing Director at F1000Research, talks about this collaborative effort and encourages all those with expertise to review COVID-19 research to sign up to the rapid reviewer list.
Read more

COVID-19 on F1000Research

A selection of our latest published research


Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates

Yu Wai Chen, Chin-Pang Bennu Yiu, Kwok-Yin Wong

Chen et al. utilised a 3D model of the SARS-CoV-2 3C-like protease to screen for potential inhibitors. Hepatitis C treatments ledipasvir or velpatasvir were identified as potential inhibitors with minimal associated side-effects, as were their dual component variants that are combined with sofosbuvir that inhibits the viral RNA-dependent RNA polymerase.

In silico identification of vaccine targets for 2019-nCoV

Chloe H. Lee, Hashem Koohy

Lee et al. aligned the proteome of SARS-CoV-2 to viral immunogenic peptides to identify potential vaccine targets. The authors were able to identify 63 potential peptides with high immunogenicity potential based on HLA allele binding and T Cell receptor recognition potential.

Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China

Robert L. Kruse

The author discusses potential therapeutic strategies ranging from repurposing small molecule inhibitors to biologics. A biologic using a soluble version of the ACE2 viral target combined with a immunoglobin Fc domain is proposed as the most effective, which will provide a neutralizing therapy that will also recruit the immune system.


COVID-19: Strategies for Online Engagement of Remote Learners

Zayabalaradjane Zayapragassarazan

This document presents a variety of strategies for increasing and ensuring higher levels of student engagement in online teaching during the COVID-19 outbreak.

Slides and posters

COVID-19 in children; is there an impact of Waldeyers Lymphatic Ring?
S Hummernbrum, G Tenzing, J Wilde

All COVID-19 research